Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine Efficacy and Safety in Japanese Patients with MDD
NCT02389816Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2015
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vortioxetine in major depressive disorder (MDD) (3 arms), sponsored by Takeda. Primary endpoint: Change From Baseline in Montgomery-Åsberg Depression Rating Scale Total Score at 8 weeks. Started Apr 2015; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02389816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02389816.